Genitourinary (GU) Tumors

1 clinical trials · Condition

Record	Firm	Date
A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy (NCT01685255)	Incyte Corporation	2012-08-01

Every clearance here is in the API, with alerts when new ones post.